启明创投

@author-1788515151757110

297 articles

Articles

Dialogue | Has the AI Cognitive Revolution Already Arrived?

Dialogue | Has the AI Cognitive Revolution Already Arrived?

Alex Zhou, Managing Partner at Qiming Venture Partners, and Dr. Wei Liu, Founder and CEO of Qiming portfolio company Video Rebirth, engaged in an in-depth dialogue on core topics including the evolution path of AI technology, industry transformation trends, startup competition, and global expansion strategy — shedding light on the technological trends of the AI 2.0 era and the breakthrough strategies for China's science and technology enterprises.

Qiming Venture Partners Portfolio Company Tashi Zhihang Unveils World's First Scalable Real-World Embodied Multimodal Dataset WIYH

Qiming Venture Partners Portfolio Company Tashi Zhihang Unveils World's First Scalable Real-World Embodied Multimodal Dataset WIYH

This achievement marks the formal establishment of Tashi Zhihang's industry-first human-centric embodied data engine paradigm — a technical approach that leads Tesla's Optimus by roughly six months.

Qiming Venture Partners Named to Tech Pioneer T50 — China's Top 50 Vanguard Tech Investment Institutions

Qiming Venture Partners Named to Tech Pioneer T50 — China's Top 50 Vanguard Tech Investment Institutions

The ranking aims to strengthen industry consensus around the commercialization of early-stage technology, guiding investment institutions to more precisely align with the strategies of "investing early and small," nurturing innovation across the full sci-tech lifecycle, and channeling capital toward strategic emerging industries.

Qiming Venture Partners and Eight Portfolio Companies Named to China Innovative Drug Decade Honors List

Qiming Venture Partners and Eight Portfolio Companies Named to China Innovative Drug Decade Honors List

The list aims to honor outstanding institutions, companies, and major innovations that have delivered exceptional performance over the past decade while playing a significant leading and driving role in the upgrade of China's innovative pharmaceutical industry — establishing benchmarks for the sector's next ten-year journey.